Common origin but individual outcomes: Time for new guidelines in personalized healthcare

Personalized Medicine

Volumn 7, Issue 5, 2010, Pages 561-568

  Golubnitschaja, Olga ^a,b   Costigliola, Vincenzo ^b  

^a UNIVERSITY OF BONN   (Germany)

^b European Association for Predictive   (Belgium)

Author keywords

blood biomarkers; effective costs; healthy individuals; perinatal diagnostics; personalized medicine; predictive diagnosis; predisposition; targeted prevention

Indexed keywords

AGING; DIABETES MELLITUS; DISEASE SEVERITY; EMERGENCY CARE; HEALTH CARE; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; LONG TERM CARE; MENTAL HEALTH; NONHUMAN; PATIENT CARE; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

EID: 77957588335     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.10.42     Document Type: Review

References (45)

1. Costigliola V, Gahan P, Golubnitschaja O: Predictive Medicine as the New Philosophy in Healthcare. In: Predictive Diagnostics and Personalized Treatment: Dream or Reality? Golubnitschaja O (Ed.). Nova Science Publishers, NY, USA (2009). • Overall concept of predictive, preventive and personalized medicine as the medicine of future: the key stakeholders and coordinated measures are presented.
2. Golubnitschaja O: Time for new guidelines in advanced diabetes care: paradigm change from delayed interventional approach to predictive, preventive and personalized medicine. EPMA J. 1, 3-12 (2010). • Overview of the most advanced technologies in predictive diagnostics, targeted preventive measures and individualized treatment algorithms in desirable diabetes care.
3. Charmandari E, Tsigos C, Chrousos G: Endocrinology of the stress response. Annu. Rev. Physiol. 67, 259-284 (2005). (Pubitemid 40409509)
4. Kultz D: Molecular and evolutionary basis of the cellular stress response. Annu. Rev. Physiol. 67, 225-257 (2005). (Pubitemid 40404492)
5. Kultz D: Evolution of the cellular stress proteome: from monophyletic origin to ubiquitous function. J. Exp. Biol. 206, 3119-3124 (2003). (Pubitemid 37181411)
6. Golubnitschaja O: Cell cycle checkpoints: the role and evaluation for early diagnosis of senescence, cardiovascular, cancer, and neurodegenerative diseases. Amino Acids 32, 359-371 (2007). (Pubitemid 46559587)
7. Massague J: G1 cell-cycle control and cancer. Nature 432, 298-306 (2004). (Pubitemid 39551657)
8. Golubnitschaja O, Flammer J: What are the biomarkers in glaucoma? Surv. Ophthalmol. 52 (Suppl. 2), 155-161 (2007).
9. Golubnitschaja O, Yeghiazaryan K, Orgül S et al.: What are the biomarkers for glaucoma? In: Predictive Diagnostics and Personalized Treatment: Dream or Reality. Golubnitshaja O (Ed.). Nova Science Publishers, NY, USA (2009). (Pubitemid 350060967)
10. Peeva V, Golubnitschaja O: Birth asphyxia as the most frequent perinatal complication. In: Predictive Diagnostics and Personalized Treatment: Dream or Reality. Golubnitschaja O (Ed.). Nova Science Publishers, NY, USA (2009).
11. Thompson DG: Consequences of perinatal asphyxia. AACN Clin. Issues Crit. Care Nurs. 5, 242-245 (1994).
12. Simon NP: Long-term neurodevelopmental outcome of asphyxiated newborns. Clin. Perinatol. 26, 767-778 (1999).
13. Maneru C, Junque C, Botet F et al.: Neuropsychological long-term sequelae of perinatal asphyxia. Brain. Inj. 15, 1029-1039 (2001). (Pubitemid 33120961)
14. Nouri S, Mahdhaoui N, Beizig S et al.: Acute renal failure in full term neonates with perinatal asphyxia. Prospective study of 87 cases. Arch. Pediatr. 15, 229-235 (2008).
15. 2 does not protect the myocardium in hypoxic newborn piglets. Arch. Dis. Child. Fetal Neonatal Ed. 89, 156-160 (2004). (Pubitemid 38338815)
16. Lubec B, Chiappe-Gutierrez M, Hoeger H et al.: Glucose transporters, hexokinases and phosphofructokinase in brain or rats with perinatal asphyxia. Pediatr. Res. 47, 84-88 (2000). (Pubitemid 30038896)
17. Seidl R, Stockler-Ipsiroglu S, Rolinski B et al.: Energy metabolism in graded perinatal asphyxia of the rat. Life Sci. 67, 421-435 (2000). (Pubitemid 30413923)
18. Numagami Y, Zubrow AB, Mishra OP et al.: Lipid free radical generation and brain cell membrane alteration following nitric oxide synthase inhibition during cerebral hypoxia in the newborn piglet. J. Neurochem. 69, 1542-1547 (1997). (Pubitemid 27406955)
19. Akhter W, Ashraf QM, Zanelli SA et al.: Effect of graded hypoxia on cerebral cortical genomic DNA fragmentation in newborn piglets. Biol. Neonate 79, 187-193 (2001). (Pubitemid 32247084)
20. Labudova O, Schuller E, Yeghiazaryan K et al.: Genes involved in the pathophysiology of perinatal asphyxia. Life Sci. 64, 1831-1838 (1999). (Pubitemid 29215204)
21. Lubec B, Labudova O, Hoeger H et al.: Expression of transcription factors in the brain of rats with perinatal asphyxia. Biol. Neonate 81, 266-278 (2002). (Pubitemid 34507595)
22. Andersson K, Blum M, Chen Y et al.: Perinatal asphyxia increases bFGF mRNA levels and DA cell body number in the mesencephalon of rats. Neuroreport 6, 375-378 (1995).
23. Cheng Y, Gidday JM, Yan Q et al.: Marked age-dependent neuroprotection by brainderived neurotrophic factor against neonatal hypoxic-ischemic brain injury. Ann. Neurol. 41, 521-529 (1997). (Pubitemid 27169192)
24. Gluckman PD, Guan J, Williams C et al.: Asphyxial brain injury - the role of the IGF system. Mol. Cell. Endocrinol. 140, 95-99 (1998). (Pubitemid 28375218)
25. Gustafson K, Hagberg H, Bengtsson BA et al.: Possible protective role of growth hormone in hypoxia-ischemia in neonatal rats. Pediatr. Res. 45, 318-323 (1999). (Pubitemid 29157761)
26. Morales P, Klawitter V, Johansson S et al.: Perinatal asphyxia impairs connectivity and dopamine neurite branching in organotypic triple culture from rat substantia nigra. Neurosci. Lett. 348, 175-179 (2003). (Pubitemid 36976834)
27. Morales P, Reyes P, Klawitter V et al.: Effects of perinatal asphyxia on cell proliferation and neuronal phenotype evaluated with organotypic hippocampal cultures. Neuroscience 135, 421-431 (2005). (Pubitemid 41317381)
28. Klawitter V, Morales P, Johansson S et al.: Effect of perinatal asphyxia on cell survival, neuronal phenotype and neurite growth evaluated with organotypic triple cultures. Amino Acids 28, 149-155 (2005). (Pubitemid 40500943)
29. Yeghiazaryan K, Peeva V, Morelli M et al.: Potential targets for early diagnosis and neuroprotection in asphyxiated newborns. In: Predictive Diagnostics and Personalized Treatment: Dream or Reality. Golubnitschaja O (Ed.). Nova Science Publishers, NY, USA (2009).
30. Lee AC, Mullany LC, Tielsch JM et al.: Risk factors for neonatal mortality due to birth asphyxia in southern Nepal: a prospective, community-based cohort study. Pediatrics 121, 1381-1390 (2008).
31. Beltrame JF, Sasayama S, Maseri A: Racial heterogeneity in coronary artery vasomotor reactivity: differences between Japanese and Caucasian patients. J. Am. Coll. Cardiol. 33, 1442-1452 (1999).
32. Flammer J: Glaucoma. A guide for patients. An Introduction For Care Providers. A Quick Reference (3rd Edition). Bern, Hogrefe and Huber Publishers, Göttingen, Germany (2006).
33. Flammer J, Pache M, Resink T: Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. Prog. Retin. Eye Res. 20, 319-349 (2001). (Pubitemid 32245685)
34. Teuchner B, Orgül S, Ulmer H et al.: Reduced thirst in patients with a vasospastic syndrome. Acta Ophthalmol. Scand. 82, 738-740 (2004). (Pubitemid 40057786)
35. Wunderlich K, Zimmerman C, Gutmann H et al.: Vasospastic persons exhibit differential expression of ABC-transport proteins. Mol. Vis. 9, 756-761 (2003). (Pubitemid 38097641)
36. Flammer J: Innovative glaucoma therapy. Ophthalmologe 98, 923-924 (2001).
37. Yeghiazaryan K, Flammer J, Golubnitschaja O: Predictive molecular profiling in blood of healthy vasospastic individuals: clue to targeted prevention as personalized medicine to effective costs. EPMA J. 1(2), 263-272 (2010).
38. Golubnitschaja O, Yeghiazaryan K, Wunderlich K et al.: Disease proteomics reveals altered basic gene expression regulation in leukocytes of glaucoma patients. Proteomics Clin. Appl. 1, 1316-1323 (2007).
39. Gahan PB: Circulating nucleic acids in plasma and serum: roles in diagnosis and prognosis. In: Diagnostics and Personalized Treatment: Dream or Reality. Golubnitschaja O (Ed.). Nova Science Publishers, NY, USA (2009). • Overview of circulating nucleic acids in plasma and serum-related strategies as one of the most potent approaches to diagnose severe pathologies and to prognose the efficacy of personalized treatments.
40. Golubnitschaja O: Diabetes mellitus, introduction. In: Predictive Diagnostics and Personalized Treatment: Dream or Reality? Golubnitschaja O (Ed.). Nova Science Publishers, NY, USA (2009).
41. Golubnitschaja O: Advanced diabetes care: three levels of prediction, prevention and personalized treatment. Curr. Diabetes Rev. 6, 42-51 (2010).
42. George B, Cebioglu M, Yeghiazaryan K: Inadequate diabetic care: global figures cry for preventive measures and personalized treatment. EPMA J. 1, 13-18 (2010).
43. Cebioglu M, Schild HH, Golubnitschaja O: Diabetes mellitus as a risk factor for cancer: is predictive diagnosis possible? In: Predictive Diagnostics and Personalized Treatment: Dream or Reality? Golubnitschaja O (Ed.). Nova Science Publishers, NY, USA (2009).
44. van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, Dercksen MW, Coebergh JW, Haak HR: Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based ana lysis. Int. J. Cancer 120, 1986-1992 (2007). (Pubitemid 46418378)
45. Cebioglu M, Schild HH, Golubnitschaja O: Cancer predisposition in diabetics: risk factors considered for predictive diagnostics and targeted preventive measures. EPMA J. 1, 130-137 (2010). • Innovative view over cancer origin: risk factors and molecular pathomechanisms are discussed.